Study : LEVOBUPIVACAINE Versus Placebo

The study will be done at the department of Obstétric and gynecology, in the CHU of Saint-Etienne. It will include all patients requiring a caesarean without any contraindication.

All the patients requiring a urgent or a very urgent caesarean will be excluded because a rapid consent can't be obtained and the product preparation can't be done.

Inclusion after information and minimum one hour of time for consideration. Randomization : the teatment group will be randomized according to the patient number : control versus placebo : 70 patients in the group infiltration of levobupivacaïne and 70 patients in the group infiltration of a placebo. Every product will be prepared in a 30 ml syringe filled with levobupivacaïne or 0,9 % sodium chloride depending on the group of randomization. All patients will get their caesarean according to the same technique, then, before the cutaneous close, the product will be injected in the caesarean wall.

Fllow-up : supervision of the pain (morphine consumption, VAS) and of undesirable effects.

Inclusion criteria

• age > 18 years
• all patients requiring a non-urgent caesarian done according to the Misgav-Ladach technique

Exclusion criteria

• Patients requiring very urgent caesarian
• allergic to levobupivacaïne
• with previous history of alcoholism or drug addiction
• with severe hypotension or an ischemic cardiopathy badly compensated or thyrotoxicoses
• treated with first generation of IMAO (monoamine oxidase inhibitor) or with anti-arrhytmia drugs with anesthesic activity